BTMD logo

BIOTE CORP -A

BTMDNASDAQ
🏆 #4502 by market capEarnings Nov 3US Equity
$949.83▼ $47.68 (−5.02%)
Simulated price
🔔
Track BTMD
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 5.0%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$45M
Small Cap
📈Revenue Growth (YoY)
-7.8%
Declining
📊Gross Margin
68.6%
High
💵FCF Margin
14.4%
Healthy
⚖️P/S Ratio
0.2x
Cheap
Otter Score
76
Good
No chart data available for BTMD.

Trading Snapshot

Day Range
$935.63 – $961.57
52-Week Range
$1.15 – $3.26
Volume
$2.49B
Avg Volume
$2.15B
Shares Outstanding
37.6M
Next Earnings
Oct 22, 2026

Fundamentals Snapshot

Annual Revenue
$192M
Last Q Revenue
$44M
P/E Ratio
7.6
P/S Ratio
0.2x
EPS (TTM)
$0.11
Dividend Yield
—
Dilution (1yr)
−17.3%

Why Investors Own BTMD

  • ✓High-growth profile — revenue up +57.1% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 72% gross margin and 24% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

BTMD logo

BIOTE CORP -A

BTMD
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$192M▼ −2.5% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
71.5%▲ +1.3% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$36M▲ +12.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$30M▼ −22.2% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
30.8M▼ −17.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$86M▼ −$14M YoY
StockOtter · stockotter.space

About BIOTE CORP -A

Biote Corp. is dedicated to supporting and developing medical practices that focus on hormone optimization. The company provides a comprehensive system for its Biote-certified healthcare professionals, enabling them to correct imbalances in patients' hormone, vitamin, and mineral levels. This includes authorizing the prescription of bioidentical hormone treatments and suggesting suitable dietary supplements. Furthermore, Biote offers its own line of branded nutritional supplements and supplies sterile kits for inserting hormone pellets for both male and female individuals. Founded in 2011, Biote Corp. is based in Irvine, Texas.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Good
76/100

Analyst Ratings

ⓘ
Consensus
Buy
11 analysts
Strong Buy3
Buy6
Hold2
Sell0
Strong Sell0
Ratings as of Sep 2026

Latest News & Updates

🚀
Barron’s·2h ago

BIOTE CORP -A tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Reuters·5h ago

Analysts lift BTMD price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Reuters·1d ago

BIOTE CORP -A announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.